Filtros de búsqueda

Lista de obras de

Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer

artículo científico publicado en 2017

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.

artículo científico publicado en 2018

Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan

artículo científico publicado en 2012

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehen

artículo científico publicado en 2017

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer

artículo científico publicado en 2018

Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer

scientific article published on 01 May 2019

Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing

artículo científico publicado en 2019

Multicenter phase 1/2 Trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial)

artículo científico publicado en 2020

Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer

artículo científico publicado en 2019

Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer

artículo científico publicado en 2018

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients

artículo científico publicado en 2015

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer

scientific article published on 13 November 2019

Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials

artículo científico publicado en 2018

Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.

artículo científico publicado en 2013

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda